… erlotinib and gefitinib in clinical practice. Type of TK inhibitors did not influence treatment
outcomes in patients with EGFR mutation or wild-type EGFR. … EGFR TKIs in patients with EGFR …

… EGFR TKI therapy against chemotherapy or placebo. We extracted data from the EGFR TKI
… ) adverse events (AEs), and discontinuation of treatment because of AE for each EGFR TKI. …

… EGFR-tyrosine kinase inhibitor (TKI) shows a durable response against NSCLC harboring
EGFR … following first-line EGFR-TKIs [first- and second-generation (G) TKIs]. When resistant …

… EGFR TKIs, ie., gefitinib monotherapy, erlotinib monotherapy, afatinib monotherapy, or any
two of them, in NSCLC patients and reported results on at least one of the following outcomes…

… EGFR-TKIs fared better than chemotherapy in terms of PFS. … gefitinib versus erlotinib 0.96
(95% CI 0.69–1.34), gefitinib … gefitinib versus erlotinib 0.80 (95% CI 0.63–1.01), gefitinib versus …

… The biological activity was associated with the potential difference in tumor sensitivity of
EGFR TKIs. The pharmacokinetic data was in good agreement with the efficacious rankings …

… In recent years, this led to the emergence of a new class of agents, the tyrosine kinase
inhibitors (TKIs). Two small-molecule EGFR TKIs, gefitinib (Iressa™) and erlotinib (Tarceva™), …

… sensitive EGFR mutations. The first-generation EGFR-TKIs included icotinib, erlotinib and
gefitinib… EGFR-TKIs in advanced NSCLC patients harboring EGFR mutations (13). However, in …

… of the power of EGFR TKIs in patients with EGFR mutations: a historical … gefitinib approval
in Japan, in conjunction with EGFR mutational status, overall survival of patients with EGFR …

… the effects of erlotinib 150 mg/d in EGFR mutated patients resistant to gefitinib 250 mg/d,
because the EGFR TKI erlotinib is given at a higher biologically active dose than gefitinib. …